Located in the US, India and Taiwan, StemCyte has established one of the largest, most racially diverse, and highest quality cord blood stem cell banks in the world. StemCyte has supplied over 900 cord blood products for over 40 life-threatening diseases to over 150 leading worldwide transplant centers.

Learn More >>

StemCyte recently participated in a clinical study involving the use of umbilical cord blood to treat thalassemia, a devastating worldwide disease. The promising engraftment and survival rate (89%) results suggest the feasibility of unrelated umbilical cord blood transplantation using StemCyte's proprietary plasma depleted cord blood products to treat children with beta-thalassemia major.

Learn More >>